Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 7Genitourinary 6Head & Neck 3Thoracic 2Sarcoma 2Lymphoid 2Gastrointestinal 2Breast 2Other solid neoplasm 1Other hematologic neoplasm 1CNS 1

Conditions

Lymphoma, Non-Hodgkin 2Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Neuroblastoma 1Neoplasms 1Melanoma 1Medulloblastoma 1Lymphoma 1Leukemia, B-Cell 1Leukemia 1Glioma 1Ependymoma 1

Interventions

Rituximab 376Cyclophosphamide 179Bendamustine Hydrochloride 109obinutuzumab 100Vincristine 94fludarabine 92ibrutinib 89Prednisone 89Doxorubicin 89venetoclax 86Lenalidomide 82Gemcitabine 65acalabrutinib 48Brentuximab Vedotin 44pembrolizumab 43zanubrutinib 41Dexamethasone 41idelalisib 37ofatumumab 32Oxaliplatin 30Chlorambucil 29polatuzumab vedotin 25blinatumomab 25tocilizumab 24Azacitidine 24tositumomab I-131 22Prednisolone 22tisagenlecleucel 21glofitamab 21Nivolumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × bempegaldesleukin × Lymphoid × Clear all
NCT04730349 2023-03-24

PIVOT IO 020

Bristol-Myers Squibb

Phase 1/2 Terminated
15 enrolled 14 charts
CNSDermatologicLymphoidOther hematologic neoplasmSarcoma

Ependymoma, Glioma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Melanoma, Neoplasms, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Leukemia, B-Cell

NCT03772288 2023-02-08

A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)

Calithera Biosciences, Inc

Phase 1 Withdrawn
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡